Prelude Therapeutics (PRLD) Net Cash Flow (2019 - 2026)

Prelude Therapeutics (PRLD) has 8 years of Net Cash Flow data on file, last reported at -$13.5 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 148.57% year-over-year to -$13.5 million; the trailing twelve-month figure through Mar 2026 stood at -$19.3 million (down 224.16% YoY), and the FY2025 full-year result was $22.0 million, up 271.44% from the prior year.
• Net Cash Flow fell to -$13.5 million in Q1 2026, from -$12.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $27.8 million in Q1 2025 to a low of -$21.4 million in Q4 2022.
• A 5-year average of -$640058.8 and a median of -$584000.0 in 2024 frame the typical range for Net Cash Flow.
• Peak annual rise in Net Cash Flow reached 4859.42% in 2025, while the deepest fall reached 1016.12% in 2025.
• Tracing PRLD's Net Cash Flow over 5 years: stood at -$21.4 million in 2022, then soared by 143.87% to $9.4 million in 2023, then slumped by 85.74% to $1.3 million in 2024, then plunged by 1016.12% to -$12.3 million in 2025, then slipped by 9.97% to -$13.5 million in 2026.
• Business Quant data shows PRLD's Net Cash Flow at -$13.5 million in Q1 2026, -$12.3 million in Q4 2025, and $21.0 million in Q3 2025.